<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03348735</url>
  </required_header>
  <id_info>
    <org_study_id>R017007</org_study_id>
    <nct_id>NCT03348735</nct_id>
  </id_info>
  <brief_title>Localized Neuropathic Pain: Topical Treatment Versus Systemic Treatment</brief_title>
  <acronym>PELICAN</acronym>
  <official_title>Safety, Efficacy and Patient Acceptability of Topical Treatment Versus Systemic Treatment: a Randomized, Multicentre, Comparative Pragmatic Trial in Adult Patients Suffering From Diverse Localized Neuropathic Pain (LNP) Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of topical treatment with lidocaine 5% patch (daily administration) or capsaicin
      8% patch (periodic administration - upon reoccurrence of pain symptoms) in adult patients
      suffering from localized neuropathic pain (LNP) across a wide variety of etiologies, with a
      duration between 1 and 24 months (subacute to chronic neuropathic pain (NP)).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicentre, randomized, open-label comparative trial evaluating topical treatment options
      versus oral systemic treatment in adult patients suffering from localized neuropathic pain
      (LNP) syndromes. A wide variety of peripheral neuropathic pain syndromes will be included
      such as post-herpetic neuralgia (PHN), post-surgical NP/post-traumatic NP/scar pain,
      post-amputation NP, post-radiation therapy NP, complex regional pain syndrome (CRPS) type 1.
      In contrast to most (or even all) commercial clinical studies we will not limit the inclusion
      to one or two distinct neuropathic pain syndromes such as post-herpetic neuralgia (inclusion
      based on etiology of the neuropathic syndrome). In this pragmatic trial we will however
      include all patients suffering from a clinical neuropathic syndrome with distinct clinical
      features such as hyperalgesia/allodynia, presence of spontaneous positive sensory phenomena
      and lasting for more than 3 months without making any exclusion based on etiology. Initial
      pain intensity indicates the presence of either moderate or severe pain in these adult
      patients (NRS 4/10).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A multicentre, randomized, open-label comparative trial evaluating topical treatment options (lidocaine 5% or capsaicine 8% patch) versus oral systemic treatment (pregabaline as standard of care) in adult patients suffering from localized neuropathic pain (LNP) syndromes.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Stratified randomization by site and Neuropathic Pain Symptom Inventory (NPSI) will be applied, and coordinated centrally which randomizes eligible patients to one of three treatment arms, and assigns patient numbers. Medication will be dispensed by the hospital pharmacies of the individual participating multidisciplinary pain centres, after proper labelling.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Health-related quality of life questionnaire</measure>
    <time_frame>24 months</time_frame>
    <description>To determine if topical treatment significantly improves health-related quality of life compared to systemic treatment in adult patients suffering from localized neuropathic pain across a wide variety of etiologies (LNP), with a duration between 1 and 24 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain relief</measure>
    <time_frame>from week 0 up to 26 weeks</time_frame>
    <description>Reduction in pain intensity (PI-NRS), time to worsening of the pain (PI-NRS and NPSI) and use of rescue medication (MSQ III-R)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>from week 0 up to 26 weeks</time_frame>
    <description>AUC for EQ-5D-5L measurements, global perceived effect (GPE), effect on mood (HADS), quality of sleep (NRS and ISI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug tolerance</measure>
    <time_frame>from week 0 up to 26 weeks</time_frame>
    <description>Percentage of patients without systemic drug related side effects, percentage of patients who discontinue the study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional status of the patient</measure>
    <time_frame>from week 0 up to 26 weeks</time_frame>
    <description>Impact of pain on functioning (Interference - BPI), participation in activities (Utrecht Work Engagement Scale), Work Productivity and Activity Impairment (WPAI).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">591</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>Lidocaine patch 5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lidocaine 5% medicated plasters will be applied daily, during 12 consecutive hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capsaicin 8% patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsaicin 8% patches need to applied in a hospital setting during 1 hour. Re-application of these capsaicin patches will be performed upon re-occurrence of painful symptoms (mostly after 12 weeks - so not after a fixed time interval). Application of capsaicin patches will be carried out in a hospital setting (+/- 3 hours procedure).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabaline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral treatment with pregabalin (75mg capsules) will be used at optimized doses to best match clinical practice in Europe. In European clinical practice, up-titration of the dose is often carried out over a longer time-period. This study thus includes up-titration schedule for pregabalin over a period of 4 weeks. If patients develop side-effects during the intake/uptitration of pregabalin this treatment can be stopped and switched to gabapentin (300mg capsules). Gabapentin will always be the back-up treatment for failed systematic treatment with pregabalin. Dose of gabapentin will be uptitrated to maximum 1200mg per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine patch 5%</intervention_name>
    <description>Application of Lidocaine 5% patch for 12 hours.</description>
    <arm_group_label>Lidocaine patch 5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capsaicin 8% Patch</intervention_name>
    <description>Application of Capsaicin 8% patch for</description>
    <arm_group_label>Capsaicin 8% patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Oral treatment with pregabalin (75mg capsules) will be used at optimized doses to best match clinical practice in Europe.</description>
    <arm_group_label>Pregabaline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients eligible for inclusion in this study must fulfil all of the following criteria:

          -  Subjects should be capable of giving their informed consent with sufficient knowledge
             of the Dutch, French or German language;

          -  Males and females, 18 years and older;

          -  Be assessed as suffering from moderate to severe neuropathic pain across the screening
             process with pain intensity (numeric rating scale - NRS) ≥ 4/10,

          -  At the time of screening pain symptoms have to be present for at least one (1) month,
             with a maximum of 24 months;

          -  Sensory disturbances present in the skin area of maximal pain;

          -  At the time of screening pain is clearly related to the presence of a localized
             neuropathic pain syndrome.

          -  Male or female patients of child producing potential* must agree to use contraception
             or take measures to avoid pregnancy during the study and until after the final
             treatment;

          -  Women can only be included after negative pregnancy test;

        Exclusion Criteria:

          -  Age &lt; 18;

          -  Pregnant and breastfeeding women;

          -  Infection in the painful skin region;

          -  Poorly healed or non-healed wound or scar in the painful skin region as well as
             presence of cutaneous abnormalities (non-intact skin barrier) within the painful skin
             region related to dermatological conditions;

          -  Known and/or strong suspicion of allergy to the study medication, known skin disorder
             (resulting in disruption of the normal skin barrier);

          -  Previous treatment with any of the three medications included in the study protocol
             for the same painful area within the last 12 months at the time of screening;

          -  Risk of heart failure and/or renal failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy Hans, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elke Smits, MD, PhD</last_name>
    <phone>03 821 40 49</phone>
    <phone_ext>0032</phone_ext>
    <email>elke.smits@uza.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Inge Michielsens</last_name>
    <phone>03 821 44 03</phone>
    <phone_ext>0032</phone_ext>
    <email>inge.michielsens@uza.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University hospital Antwerp</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davina Wildemeersch, MD</last_name>
      <phone>03 821 58 91</phone>
      <phone_ext>0032</phone_ext>
      <email>davina.wildemeersch@uza.be</email>
    </contact>
    <investigator>
      <last_name>Davina Wildemeersch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristof Deseure, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcel Vercauteren, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guy Hans, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Ceuppens</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hilde De Belder</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadia Meysman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ella Roelant</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Monica (campus Antwerpen)</name>
      <address>
        <city>Antwerp</city>
        <zip>2018</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Brzezinska</last_name>
      <email>ewa.brzezinska@azmonica.be;</email>
    </contact>
    <investigator>
      <last_name>Ewa Brzezinska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Klina</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirella Dingens</last_name>
      <email>mirella.dingens@azklina.be</email>
    </contact>
    <investigator>
      <last_name>Mirella Dingenen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint Jan Brugge</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannie Braems</last_name>
      <email>hanniebraems@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hannie Braems, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UVC Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Mathieu</last_name>
      <email>nathalie.mathieu@chu-brugmann.be</email>
    </contact>
    <investigator>
      <last_name>Nathalie Mathieu, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Dangoisse</last_name>
      <email>Michel.Dangoisse@ghdc.be</email>
    </contact>
    <investigator>
      <last_name>Michel Dangoisse, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephane Nikis, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg (ZOL</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koen Van Boxem</last_name>
      <email>koen.vanboxem@zol.be</email>
    </contact>
    <investigator>
      <last_name>Koen Van Boxem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent (UZG)</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erwin Crombez</last_name>
      <email>erwin.crombez@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Erwin Crombez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milica Matic</last_name>
      <email>milica.matic@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Milica Matic, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven (UZL)</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart Morlion</last_name>
      <email>bart.morlion@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Bart Morlion</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Sart Tilman de Liège (ULg) (CHU)</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Fontaine</last_name>
      <email>robert.fontaine@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Robert Fontaine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier De Coster</last_name>
      <email>olivier.decoster@azdelta.be</email>
    </contact>
    <investigator>
      <last_name>Olivier De Coster, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout</name>
      <address>
        <city>Turnhout</city>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frans Van De Perck</last_name>
      <email>Frans.VanDePerck@azturnhout.be</email>
    </contact>
    <investigator>
      <last_name>Frans Van De Perck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 16, 2017</study_first_submitted>
  <study_first_submitted_qc>November 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2017</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>Davina Wildemeersch</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

